KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Other Operating Expenses (2016 - 2024)

Historic Other Operating Expenses for Exact Sciences (EXAS) over the last 15 years, with Q4 2024 value amounting to $2.6 million.

  • Exact Sciences' Other Operating Expenses fell 5987.5% to $2.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 8029.47%. This contributed to the annual value of $9.2 million for FY2024, which is 8826.93% down from last year.
  • According to the latest figures from Q4 2024, Exact Sciences' Other Operating Expenses is $2.6 million, which was down 5987.5% from $3.1 million recorded in Q3 2024.
  • Over the past 5 years, Exact Sciences' Other Operating Expenses peaked at $393.5 million during Q2 2022, and registered a low of -$13.2 million during Q3 2022.
  • Its 5-year average for Other Operating Expenses is $153.2 million, with a median of $98.1 million in 2020.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 64384.63% in 2023, then plummeted by 9569.61% in 2024.
  • Over the past 5 years, Exact Sciences' Other Operating Expenses (Quarter) stood at $169.4 million in 2020, then skyrocketed by 96.32% to $332.6 million in 2021, then tumbled by 103.98% to -$13.2 million in 2022, then skyrocketed by 148.32% to $6.4 million in 2023, then plummeted by 59.88% to $2.6 million in 2024.
  • Its last three reported values are $2.6 million in Q4 2024, $3.1 million for Q3 2024, and $3.8 million during Q2 2024.